Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1681/ASN.2016091034 http://scihub22266oqcxt.onion/10.1681/ASN.2016091034 C5491290!5491290!28280140     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28280140&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Am+Soc+Nephrol 2017 ; 28 (7): 2221-32 Nephropedia Template TP {{tp|p=28280140|t=2017. Cell-Free DNA and Active Rejection in Kidney Allografts |pdf=|usr=}}{{28280140}} gab.com Text Cell-Free DNA and Active Rejection in Kidney Allografts JO: J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28280140 #FOAvip Histologic analysis of the allograft biopsy specimen is the standard method used to differentiate rejection from other injury in kidney transplants. Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and injury status. To investigate this possibility, we prospectively collected blood specimens at scheduled intervals and at the time of clinically indicated biopsies. In 102 kidney recipients, we measured plasma levels of dd-cfDNA and correlated the levels with allograft rejection status ascertained by histology in 107 biopsy specimens. The dd-cfDNA level discriminated between biopsy specimens showing any rejection (T cell?mediated rejection or antibody-mediated rejection [ABMR]) and controls (no rejection histologically), P<0.001 (receiver operating characteristic area under the curve [AUC], 0.74; 95% confidence interval [95% CI], 0.61 to 0.86). Positive and negative predictive values for active rejection at a cutoff of 1.0% dd-cfDNA were 61% and 84%, respectively. The AUC for discriminating ABMR from samples without ABMR was 0.87 (95% CI, 0.75 to 0.97). Positive and negative predictive values for ABMR at a cutoff of 1.0% dd-cfDNA were 44% and 96%, respectively. Median dd-cfDNA was 2.9% (ABMR), 1.2% (T cell?mediated types ?IB), 0.2% (T cell?mediated type IA), and 0.3% in controls (P=0.05 for T cell?mediated rejection types ?IB versus controls). Thus, dd-cfDNA may be used to assess allograft rejection and injury; dd-cfDNA levels <1% reflect the absence of active rejection (T cell?mediated type ?IB or ABMR) and levels >1% indicate a probability of active rejection. Twit Text FOAVip Cell-Free DNA and Active Rejection in Kidney Allografts ????J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28280140 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28280140 #FOAvip English Wikipedia <ref>{{Cite pmid|28280140}}</ref> Cell-Free DNA and Active Rejection in Kidney Allografts #MMPMID28280140 Bloom RD; Bromberg JS; Poggio ED; Bunnapradist S; Langone AJ; Sood P; Matas AJ; Mehta S; Mannon RB; Sharfuddin A; Fischbach B; Narayanan M; Jordan SC; Cohen D; Weir MR; Hiller D; Prasad P; Woodward RN; Grskovic M; Sninsky JJ; Yee JP; Brennan DC; Bloom RD; Bromberg JS; Poggio E; Bunnapradist S; Langone A; Sood P; Matas A; Mehta S; Mannon RB; Sharfuddin A; Fischbach B; Narayanan M; Jordan S; Cohen D; Weir M; Hiller D; Prasad P; Woodward RN; Grskovic M; Sninsky J; Yee JP; Brennan DC J Am Soc Nephrol 2017[Jul]; 28 (7): 2221-32 PMID28280140show ga Histologic analysis of the allograft biopsy specimen is the standard method used to differentiate rejection from other injury in kidney transplants. Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and injury status. To investigate this possibility, we prospectively collected blood specimens at scheduled intervals and at the time of clinically indicated biopsies. In 102 kidney recipients, we measured plasma levels of dd-cfDNA and correlated the levels with allograft rejection status ascertained by histology in 107 biopsy specimens. The dd-cfDNA level discriminated between biopsy specimens showing any rejection (T cell?mediated rejection or antibody-mediated rejection [ABMR]) and controls (no rejection histologically), P<0.001 (receiver operating characteristic area under the curve [AUC], 0.74; 95% confidence interval [95% CI], 0.61 to 0.86). Positive and negative predictive values for active rejection at a cutoff of 1.0% dd-cfDNA were 61% and 84%, respectively. The AUC for discriminating ABMR from samples without ABMR was 0.87 (95% CI, 0.75 to 0.97). Positive and negative predictive values for ABMR at a cutoff of 1.0% dd-cfDNA were 44% and 96%, respectively. Median dd-cfDNA was 2.9% (ABMR), 1.2% (T cell?mediated types ?IB), 0.2% (T cell?mediated type IA), and 0.3% in controls (P=0.05 for T cell?mediated rejection types ?IB versus controls). Thus, dd-cfDNA may be used to assess allograft rejection and injury; dd-cfDNA levels <1% reflect the absence of active rejection (T cell?mediated type ?IB or ABMR) and levels >1% indicate a probability of active rejection. äCell-Free DNA and Active Rejection in Kidney Allografts (epmc).pdf DeepDyve Pubget Overpricing